The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre "Real-Life" Cohort Study.

Introduction: Guselkumab is an interleukin-23 (IL-23) inhibitor licensed for the treatment of psoriatic arthritis (PsA). This study aimed to evaluate the 6-month effectiveness of guselkumab in patients with PsA in a "real-life" multicentre patient cohort. We also estimated the drug retention rate (DRR) of gusulkumab, also assessing the impact of comorbidities and patient clinical characteristics, in a collective 18-month prospective follow-up.

Low levels of heat shock proteins-60 and -65 autoantibodies in Sjögren's syndrome.

Background: Heat shock proteins are highly conserved immunodominant antigens found in various species. Humoral immune responses to mycobacterial HSP65 and human HSP60 have been established in a number of human autoimmune diseases.

Objective: To assess the prevalence of antibodies to HSP60 kDa and HSP65 kDa in patients with Sjögren's syndrome as compared to normal subjects.

Precocious intima-media thickening in patients with primary Sjögren's syndrome.

Objective: Systemic lupus erythematosus and rheumatoid arthritis represent independent risk factors for atherosclerosis (ATS), although this may be confounded by continuous pharmacologic treatment. Primary Sjögren's syndrome (SS) shares several features of these diseases and may therefore represent an interesting model for verifying the presence of accelerated ATS in the absence of pharmacologic interference. The present study therefore used this model to describe the presence of accelerated ATS in a group of young women.

[Recent views on the pathogenesis of cardiovascular damage associated with rheumatoid arthritis].

Cardiovascular disease is the commonest cause of premature mortality in rheumatoid arthritis and several data have shown that rheumatoid arthritis is an independent risk factor for the development of atherosclerotic disease. In last years it has become evident that atherosclerosis is an immune-mediated inflammatory disorder sharing a number of pathogenic features with rheumatoid arthritis. It is conceivable, therefore, that chronically raised concentrations of proinflammatory cytokines and pathological immune response characterizing rheumatoid arthritis may play a key role in inducing acceleration of atherosclerotic processes and, consequently, in the development of cardiovascular disease in these patients.

Autoantibodies profile in the sera of patients with Sjogren's syndrome: the ANA evaluation--a homogeneous, multiplexed system.

Background: Flow-based, multiplex bead arrays (MBA) have been developed for a variety of applications including the detection of antibodies to extractable nuclear antigens (ENA). It offers a rapid and sensitive method to assess multiple analyses in a single tube/well.

Purpose: To evaluate the Athena Multi-Lyte ANA Test System utilizes Luminex Corporation's MBA technology for the detection of antinuclear antibodies (ANA) and ENA antibodies in the sera of patients with Sjogren's syndrome (SS).